DHCPL, HSA Announcements

HSA DHCPL: Plaquenil® (Hydroxychloroquine sulfate) – Risk of major congenital malformations and new risks of phospholipidosis and aggravation of myasthenia gravis symptoms

Sep 29
By DocMed

Plaquenil® (Hydroxychloroquine sulfate) – Risk of major congenital malformations and new risks of phospholipidosis and aggravation of myasthenia gravis symptoms

You must be healthcare professional to view this content.

EXPLORE

The Role Of Melatonin in Treating Insomnia

Be aware of skin cancer symptoms, get those new growths checked

Comprehensive Protection Against Pneumococcal Infections with PCV20

New Drug Offers Hope in Extending Survival for HER2-Positive Breast Cancer Patients

A Specialist’s Point Of View: Atopic Dermatitis

HSA DHCPL: Plaquenil® (Hydroxychloroquine sulfate) – Risk of major congenital malformations and new risks of phospholipidosis and aggravation of myasthenia gravis symptoms

You must be healthcare professional to view this content.

EXPLORE

RELATED CONDITIONS &

PROCEDURES

About Us

Our Section

Connect with Us

My Account